CompletedNCT00252226
Quetiapine to prevent relapse in adolescents with bipolarity
About this title
Read the official source — NCT00252226This study evaluated the effectiveness of Quetiapine for people with bipolarity.
Medication studyAges 12–20Canada
Understand this study
What did researchers investigate?
This study evaluated the effectiveness of Quetiapine for people with bipolarity.
Who was this study for?
Listed age limits: 12 years to 20 years.
- Listed locations
- OttawaSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJune 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 100
- Sponsor
- Mood Disorders Center of Ottawa
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Canada
- Age range
- From 12 Years to 20 Years
- Official registry ID
- NCT00252226
- Official title
Show the full official title
Quetiapine (Seroquel) Maintenance Treatment in Early Onset Bipolar Spectrum Disorders: An Open Prospective Longitudinal Study of the Effectiveness of Quetiapine Monotherapy in Preventing Relapse and Minimizing Neurocognitive Dysfunction Among Adolescents Manifesting Bipolar Spectrum Disorders
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Ottawa
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the effectiveness of Quetiapine for people with bipolarity.
Who is behind this study?
The study sponsor is Mood Disorders Center of Ottawa.
Did this study involve medication?
Yes. The study involved medication, including Quetiapine.
Who was this study for?
Listed age limits: 12 years to 20 years.
